Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 21, 2021SHILAP Revista de lepidopterologíaOpen Access

Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial

View Full Paper
Ask AI
Bookmark
Share

Authors

NPNoemí PuigMHMiguel‐Teodoro HernándezLRLaura Rosiñol

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Puig et al. (2021) studied this question.

synapsesocial.com/papers/69d9d9a85e5bcb4e3b838065https://doi.org/10.1038/s41408-021-00490-8
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1BLT-D (Clarithromycin [Biaxin], Low-Dose Thalidomide, and Dexamethasone) for the Treatment of Myeloma and Waldenström's Macroglobulinemia2002 · 79 citations
  2. 2Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial2019 · 45 citations
  3. 3Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma2019 · 1,020 citations
  4. 4Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study2014 · 385 citations
  5. 5Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study2020 · 36 citations